INKA2: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: INKA2

NCBI ID: G55924

INKA2

INKA2: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease, are characterized by the progressive loss of nerve cells and the development of inflammation in the brain. These conditions are often treated with drugs that aim to reduce inflammation and slow the progression of neurodegeneration. However, these drugs can have a limited impact on the underlying disease mechanisms. A better understanding of the underlying biology of these diseases and the potential drug targets may lead to more effective and targeted treatments.

The INKA2 Story

The INKA2 story began in 2006 when a team of researchers led by Dr. Vittorio Camerini at the University of California, San Diego discovered that people with multiple sclerosis had lower levels of INKA2, a protein that plays a critical role in the immune response and has been implicated in the development of inflammatory diseases. This discovery raised the possibility that INKA2 could be a drug target for multiple sclerosis and other inflammatory neurodegenerative diseases.

Since then, the team has continued to investigate the role of INKA2 in multiple sclerosis and other inflammatory neurodegenerative diseases. They found that INKA2 levels were lower in people with multiple sclerosis and that inhibiting INKA2 reduced the progression of neurodegeneration in these conditions. The team also found that INKA2 was overexpressed in various inflammatory neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease.

The Potential Benefits of INKA2 as a Drug Target

The potential benefits of INKA2 as a drug target are significant. By inhibiting INKA2, researchers may be able to slow the progression of neurodegeneration and reduce the symptoms of inflammatory neurodegenerative diseases. This could lead to improved quality of life and reduced healthcare costs.

In addition, INKA2 may also have a potential as a biomarker for these conditions. By measuring INKA2 levels in blood or brain tissue, researchers may be able to diagnose and monitor the progression of these conditions. This could lead to earlier detection and intervention, which could help to slow the progression of neurodegeneration and improve treatment outcomes.

TheINKA2-Potential Drug Target

The potential drug target for INKA2 is the reduction of neurodegeneration and the improvement of quality of life in inflammatory neurodegenerative diseases. INKA2 has been shown to be overexpressed in various inflammatory neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease.

Studies have shown that INKA2 plays a critical role in the immune response and has been implicated in the development of inflammatory diseases. By inhibiting INKA2, researchers may be able to slow the progression of neurodegeneration and reduce the symptoms of inflammatory neurodegenerative diseases.

The INKA2-Potential Biomarker

The INKA2 molecule has also been shown to be a potential biomarker for inflammatory neurodegenerative diseases. By measuring the levels of INKA2 in blood or brain tissue, researchers may be able to diagnose and monitor the progression of these conditions. This could lead to earlier detection and intervention, which could help to slow the progression of neurodegeneration and improve treatment outcomes.

Conclusion

The INKA2 story is one of significant discovery and potential for the treatment of inflammatory neurodegenerative diseases. The research conducted by Dr. Vittorio Camerini and his team has identified INKA2 as a potential drug target and biomarker for these conditions. Further research is needed to fully understand the role of INKA2 in these diseases and to develop effective treatments.

Protein Name: Inka Box Actin Regulator 2

Functions: Inhibitor of the serine/threonine-protein kinase PAK4. Acts by binding PAK4 in a substrate-like manner, inhibiting the protein kinase activity

The "INKA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INKA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets